Jeffrey Hatfield Net Worth

Jeffrey Hatfield biography

Jeffrey S. Hatfield serves as Independent Chairman of the Board of the Company. Mr. Hatfield has served as a member of our Board since August 2017. Mr. Hatfield is a veteran biotechnology and pharmaceutical industry leader, with over three decades of experience. Mr. Hatfield is currently the chief executive officer of Zafgen, Inc. Previously, he served as president and chief executive officer of Vitae Pharmaceuticals, Inc., until its acquisition by Allergan in 2016. Prior to working at Vitae Pharmaceuticals, Inc., Mr. Hatfield served in numerous executive capacities at Bristol-Myers Squibb Company (“BMS”) including senior vice president of BMS’s Immunology and Virology divisions, president of BMS Canada, and head of U.S. market access. Mr. Hatfield currently serves as a director on the boards of publicly traded biotechnology companies aTyr Pharma, Inc. and Zafgen, Inc., and has previously served as a director of Ambit Biosciences Corporation, prior to its acquisition by Daiichi Sankyo Company, Ltd., and InVivo Therapeutics, Inc. He is an adjunct professor and a dean’s advisory board member for Purdue University’s College of Pharmacy. He earned a B.S. degree in pharmacy from Purdue University’s College of Pharmacy and an M.B.A. degree from The Wharton School at the University of Pennsylvania.

What is the salary of Jeffrey Hatfield?

As the Independent Chairman of the Board of Miragen Therapeutics Inc, the total compensation of Jeffrey Hatfield at Miragen Therapeutics Inc is $95,303. There are 2 executives at Miragen Therapeutics Inc getting paid more, with Diana Escolar having the highest compensation of $543,788.

How old is Jeffrey Hatfield?

Jeffrey Hatfield is 62, he's been the Independent Chairman of the Board of Miragen Therapeutics Inc since 2018. There are 2 older and 7 younger executives at Miragen Therapeutics Inc. The oldest executive at Miragen Therapeutics Inc is Arlene Morris, 68, who is the Independent Director.

What's Jeffrey Hatfield's mailing address?

Jeffrey's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158.

Insiders trading at Miragen Therapeutics Inc

Over the last 8 years, insiders at Miragen Therapeutics Inc have traded over $636,110 worth of Miragen Therapeutics Inc stock and bought 1,041,411 units worth $5,368,137 . The most active insiders traders include Bennett S Lebow, Bruce Booth, and Paul D Rubin. On average, Miragen Therapeutics Inc executives and independent directors trade stock every 91 days with the average trade being worth of $2,345,685. The most recent stock trade was executed by Global Master Fund Lp Logos on 9 November 2020, trading 476,667 units of MGEN stock currently worth $2,268,935.

What does Miragen Therapeutics Inc do?

Miragen Therapeutics Inc executives and stock owners

Miragen Therapeutics Inc executives and other stock owners filed with the SEC include:

• Diana Escolar,
  Chief Medical Officer
• Jason Leverone,
  Principal Financial Officer, Principal Accounting Officer, Treasurer, Secretary
• Jeffrey Hatfield,
  Independent Chairman of the Board
• Joseph Turner,
  Independent Director
• Arlene Morris,
  Independent Director
• Christopher Bowden,
  Independent Director
• Tomas Kiselak,
  Director
• Peter Harwin,
  Director
• Lee Rauch,
  Chief Executive Officer, Director
• Jonathan Violin,
  President, Chief Operating Officer
• Bruce Booth,
  Director
• Kyle Lefkoff,
  Director
• Paul D Rubin,
  EVP, Research & Development
• Adam Scott Levy,
  Chief Business Officer
• Thomas E. Hughes,
  Director
• Bennett S Lebow,
  Director
• Global Master Fund Lp Logos,
  10% owner
• John W Creecy,
  Director
• Kevin Koch,
  Director
• Funds Management Llc Fairmo...,
  
• William Stuart Marshall,